Dr. Reddy’s Q2 FY24 financial results show 9% YoY revenue growth

Dr. Reddy’s Laboratories Ltd., an Indian pharma major, has unveiled its robust performance metrics for the Q2 FY24, ending September 30, 2023. Under the guidelines of the International Financial Reporting Standards (IFRS), the pharmaceutical giant reported a notable YoY revenue growth of 9%, emphasizing its strong market positioning. The company’s growth trajectory, especially in regions like North America and Europe, along with detailed insights into its global generics and other segments, further fortifies its stature in the pharmaceutical world. As we delve deeper into the numbers, the financial health and strategies of Dr. Reddy’s become more evident, revealing the key drivers behind their upward momentum.

Q2 FY24 Financial Overview:

– Revenues: Rs. 68,802 Mn [Up 9% YoY; Up 2% QoQ]

– Profit before Tax: Rs. 19,134 Mn [Up 19% YoY; Up 4% QoQ]

– Profit after Tax: Rs. 14,800 Mn [Up 33% YoY; Up 6% QoQ]

Notable Insights from Q2 FY24 Results

Global Generics (GG) Segment:

– Q2 FY24 revenue at Rs. 61.1 billion, marking a YoY growth of 9% and QoQ growth of 2%, primarily driven by North America and Europe.

– North America has shown Q2 FY24 revenue at Rs. 31.7 billion with YoY growth of 13%. Four new products were launched in the US during this quarter.

– Europe registered a Q2 FY24 revenue of Rs. 5.3 billion, marking a YoY growth of 26%.

– India saw a Q2 FY24 revenue of Rs. 11.9 billion with a YoY growth of 3%.

– Emerging Markets presented a mixed performance with revenues from Russia indicating a decline while others showcased growth.

Pharmaceutical Services and Active Ingredients (PSAI):

– Q2 FY24 revenue reached Rs. 7.0 billion, highlighting a growth of 9% YoY, mainly driven by new product launches.

In-depth Analysis

Income Statement Highlights and Key Performance Metrics:

• Gross Margin: Stood at 58.7% for Q2 FY24. There was a slight decrease from the preceding year, primarily due to some price variations.
• SG&A Expenses: Accounted for Rs. 18,795 Mn, with an increase of 13% YoY.
• R&D Expenses: These expenses reached Rs. 5,447 Mn, comprising 7.9% of revenues. The investments are primarily funneled into clinical trials and other developmental efforts.

Statements from Company Officials:

Co-Chairman & MD, G V Prasad mentioned, “We delivered another quarter of strong results with highest ever sales and profits, driven by market share gains & momentum in our US generics business and robust growth in Europe.”

Additional Details

Profit before Tax for Q2 FY24 stood at Rs. 19.1 billion, marking a YoY growth of 19%. The effective tax rate was reported at 22.7%, primarily due to the adoption of corporate tax rate under section 115BAA of the Income Tax Act of India. The diluted earnings per share for Q2 FY24 is Rs. 88.78.